Industry Symposium With ACPE Credit
The Value of Early Intervention with Long-Acting Injectable Antipsychotics to Improve Adherence and Treatment of Schizophrenia
Supported by Alkermes

Registration Options

Activity Date: 04/17/2023

Session Time and Location

Session Summary

Prior to the presentation, lunch will be served from 11:15-11:30 AM Eastern. The program should begin right at 11:30 AM Eastern; however, small delays are possible due to the meal. We thank you in advance for your patience.

Schizophrenia is a mental disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions and requires continuous and effective long-term management to reduce symptoms, improve quality of life, and prevent relapses. While oral antipsychotics have proven to be efficacious for many patients, ongoing symptoms and relapse remain a problem due to nonadherence. Long-acting injectable (LAI) antipsychotics are an underutilized treatment alternative that, when administered early on, improve adherence and reduce/prevent relapses and hospitalizations. It is important that pharmacists are familiar with the substantial health and economic burdens associated with schizophrenia, including high rates of medication nonadherence and symptomatic relapses, to effectively identify patients who may be ideal candidates for LAI antipsychotics as well as counsel patients/caregivers about schizophrenia and possible treatments. This activity will discuss current guidelines and data on LAIs to enable pharmacists to make appropriate recommendations in the treatment of patients with schizophrenia.

PARTICIPATE IN POLLS

HOW TO RECEIVE CREDIT 
Please follow the instructions below to claim your credit: 

• Go to: https://www.pharmacytimes.org/aapp-2023-schizophrenia
  • To continue, you will need to be logged into your PTCE account. 
  • If you do not have a PTCE Account, create one using the prompt on the page. 
• Once logged in, answer the activity evaluation, and click ‘Complete Survey’. 
• After completing the survey, click the blue arrow button to complete the activity and request credit. 
• Your credit will be uploaded to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net

NOTE: Participation data will not be uploaded into CPE monitor if you do not have your NABP (e-profile ID) number and date of birth entered in your profile.

All participants must request credit by June 17, 2023.

Faculty Information and Disclosures

Learning Objectives

1. Analyze the factors that contribute to elevated rates of nonadherence, rates of relapse, and treatment challenges associated with schizophrenia
2. Explore the current American Psychiatric Association guidelines regarding the use of long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia
3. Examine the safety and efficacy data, including real-world data, for the FDA-approved LAI antipsychotics for the treatment of schizophrenia
4. Identify the role of the pharmacist in making clinical recommendations regarding the early use of LAI antipsychotics and in optimizing care for patients with schizophrenia to improve clinical outcomes

Continuing Education Credit and Disclosures

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

Grant Support